STOCK TITAN
  1. Home
  2. News
  3. CLDI

Calidi Biotherapeutics, Inc. - CLDI STOCK NEWS

Welcome to our dedicated page for Calidi Biotherapeutics news (Ticker: CLDI), a resource for investors and traders seeking the latest updates and insights on Calidi Biotherapeutics stock.

Calidi Biotherapeutics, Inc. (CLDI) is a clinical-stage immuno-oncology company at the forefront of advancing cancer treatment methodologies. The company specializes in the development and commercialization of innovative, stem cell-based platforms designed to enhance the delivery and effectiveness of oncolytic viruses in cancer therapy.

Calidi’s core business involves leveraging its proprietary Neuro-Cells™ and SuperNova™ technology platforms. These platforms are engineered to deliver oncolytic viruses directly to tumor sites, ensuring targeted and potent cancer cell destruction while minimizing damage to surrounding healthy tissues.

Among the company's recent achievements, Calidi has successfully completed several preclinical studies demonstrating the efficacy and safety of its therapeutic candidates. Currently, Calidi is undergoing multiple Phase I/II clinical trials to further validate these findings and advance towards regulatory approvals.

Financially, Calidi Biotherapeutics has secured significant investment and formed strategic partnerships with key players in the biotechnology and pharmaceutical industries. These collaborations aim to accelerate the development timelines and expand the potential applications of their oncolytic virus therapies.

Calidi’s commitment to innovation and excellence is evident in its robust pipeline of products and ongoing research initiatives. The company continues to explore new avenues for the application of its technologies, with the ultimate goal of offering effective and life-saving treatments for cancer patients worldwide.

For the latest updates and news about Calidi Biotherapeutics, including their ongoing clinical trials and partnerships, visit their official news section.

News

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results

Rhea-AI Summary
Calidi Biotherapeutics Inc. (CLDI) receives $5.3 million grant from CIRM to develop ovarian cancer treatment using NeuroNova. The company introduces RTNova platform for diverse tumors, appoints new board members, and secures a new patent for SuperNova technology. Financially, Calidi reports a net loss for Q4 2023 and full-year 2023, with increased research and development expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.81%
Tags
earnings
-
News

Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer

Rhea-AI Summary
City of Hope receives $5.3 million grant from CIRM to develop a treatment for metastatic ovarian cancer using Calidi's CLD-101. The grant supports preclinical translational studies, product manufacturing, and clinical trial design. CLD-101 utilizes neural stem cells to deliver an oncolytic adenovirus to tumor sites, showing promising results in chemo-resistant ovarian cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.85%
Tags
none
-
News

Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference

Rhea-AI Summary
Calidi Biotherapeutics, Inc. (CLDI) announces the development of a systemic enveloped oncolytic virotherapy platform targeting a broad range of advanced tumor types. The therapy shows promising potential in transforming tumor immune microenvironments, eradicating diverse tumors, and synergizing with other immunotherapies. Preclinical models have demonstrated efficacy in resisting virus inactivation by human serum and targeting various tumor types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
conferences
News

Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board

Rhea-AI Summary
Calidi Biotherapeutics, Inc. (CLDI) announced the appointment of three new members to its Scientific and Medical Advisory Board. These experts in oncology will support the development of novel immunotherapies targeting high-grade gliomas and solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.85%
Tags
management
-
News

Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit

Rhea-AI Summary
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) announced presentations on its NeuroNova and SuperNova allogeneic stem cell-based virotherapy platforms at the 8th Oncolytic Virotherapy Summit, including updates on clinical trials and plans for advanced solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.09%
Tags
clinical trial
-
News

Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors

Rhea-AI Summary
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) announced the appointment of David LaPré to the company’s Board of Directors effective January 1, 2024. The company also announced the resignation of Director Alfonso Zulueta effective November 29, 2023 and the resignation of Director Tom Vecchiolla effective January 1, 2024. David LaPré brings a wealth of pharmaceutical industry experience and expertise, having held senior executive roles at Roche/Genentech for over 20 years. Calidi CEO Allan Camaisa expressed confidence in LaPré's ability to advance the company's cancer immunotherapies into later stage clinical trials. Calidi Biotherapeutics is focused on delivering effective allogeneic stem cell therapies to patient populations with few effective treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
News

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones

Rhea-AI Summary
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) announced the issuance of a new patent for its SuperNova technology, strengthening its intellectual property portfolio and positioning the company to advance its CLD-201 program into the clinic. The USPTO has issued U.S. Patent No. 11,655,455 titled, 'Enhanced systems for cell-mediated oncolytic viral therapy,' directed to Calidi’s SuperNova platform. This patent represents an important milestone for Calidi as it prepares to advance CLD-201 into the clinic. The patent covers a composition where cells are incubated with an oncolytic virus for a defined period, allowing the expression of at least one immunomodulatory protein or recombinant therapeutic protein encoded by the virus. Calidi also provided updates on the timing for certain anticipated clinical milestones for its NeuroNova and SuperNova platforms, with the first patient dosed in CLD-101 (NeuroNova) Phase 1b/2 trial in collaboration with Northwestern University anticipated in 1H 2024, and the first patient dosed in CLD-201 (SuperNova) Phase 1 trial anticipated in 2H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
none
-
News

Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results

Rhea-AI Summary
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) reports financial results for Q3 2023, highlights first patient dosing in Phase 1 clinical trial for CLD-101, and presents promising preclinical data for CLD-201. Recent corporate developments include key management and board appointments, a successful business combination transaction, and upcoming milestones for clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.5%
Tags
earnings
-
News

Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023)

Rhea-AI Summary
Calidi Biotherapeutics announces new preclinical data on its CLD-201 allogeneic stem cell-based platform, demonstrating its potential to effectively target solid tumors. The company plans to initiate a Phase 1 clinical trial in 2024. CLD-201 offers advantages over autologous approaches, including enhanced potency, improved manufacturing reproducibility, and lower cost. The poster presentation highlights the evaluation of CLD-201 in in vitro and animal models, showing tumor growth inhibition and induction of anti-tumor immunity. Calidi Biotherapeutics believes that CLD-201 is a promising immunotherapy platform for treating advanced solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.9%
Tags
none
News

Calidi Biotherapeutics Announces Key Leadership Promotions and New Board Appointment

Rhea-AI Summary
Calidi Biotherapeutics, Inc. announces the promotion of Antonio Santidrian to Chief Scientific Officer and Amish Patel to Senior Vice President of Technical Operations. Alan Stewart is appointed to the Board of Directors. Santidrian will lead research and development activities, while Patel will oversee global manufacturing. Stewart brings financial expertise to the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.55%
Tags
none

FAQ

What is the current stock price of Calidi Biotherapeutics (CLDI)?

The current stock price of Calidi Biotherapeutics (CLDI) is $2.19 as of November 15, 2024.

What is the market cap of Calidi Biotherapeutics (CLDI)?

The market cap of Calidi Biotherapeutics (CLDI) is approximately 25.1M.

What is Calidi Biotherapeutics, Inc.?

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing stem cell-based platforms for enhancing oncolytic virus delivery in cancer treatment.

What technologies does Calidi Biotherapeutics use?

Calidi uses proprietary Neuro-Cells™ and SuperNova™ technology platforms to deliver oncolytic viruses directly to tumor sites.

What is the current focus of Calidi Biotherapeutics?

Calidi is currently focused on conducting Phase I/II clinical trials to validate the efficacy and safety of their therapeutic candidates.

Has Calidi Biotherapeutics achieved any recent milestones?

Yes, Calidi has completed several preclinical studies and is progressing through multiple clinical trials to further their cancer therapies.

Who are Calidi Biotherapeutics' industry partners?

Calidi has formed strategic partnerships with leading biotechnology and pharmaceutical companies to advance their treatment platforms.

What is the goal of Calidi’s stem cell-based platforms?

The goal is to enhance the delivery and potency of oncolytic viruses in treating cancer, ensuring targeted and efficient tumor cell destruction.

What are oncolytic viruses?

Oncolytic viruses are engineered viruses that selectively infect and kill cancer cells while sparing healthy tissues.

Where can I find the latest news about Calidi Biotherapeutics?

You can find the latest updates and news about Calidi Biotherapeutics on their official news section on their website.

What are the main products of Calidi Biotherapeutics?

The main products include the Neuro-Cells™ and SuperNova™ platforms designed for effective oncolytic virus delivery in cancer therapy.

What is the long-term vision of Calidi Biotherapeutics?

Calidi aims to offer effective and life-saving cancer treatments through continuous innovation and development of their stem cell-based platforms.

Stock CLDI logo
Calidi Biotherapeutics, Inc.

NYSE:CLDI

CLDI Rankings

#5191 Ranked by Market Cap
N/A Ranked by Dividends

CLDI Stock Data

25.10M
11.68M
18.16%
2.46%
1.19%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN DIEGO